A 1210477

Manufactured by Abbvie

Sourced in United States

A-1210477 is a piece of laboratory equipment. It is designed to perform specific functions within a controlled laboratory setting. The core function of this product is to assist in the scientific research and analysis processes. However, a detailed description of its specific features and capabilities cannot be provided in an unbiased and factual manner without the risk of extrapolation or interpretation.

Automatically generated - may contain errors

Lab products found in correlation

A 1331852, by Abbvie (5 mentions) Venetoclax, by Abbvie (4 mentions) Bcl xl, by Cell Signaling Technology (3 mentions) Abt 199, by Abbvie (3 mentions) A 1155463, by Abbvie (2 mentions) Bcl w, by Cell Signaling Technology (2 mentions) Mcl 1, by Santa Cruz Biotechnology (2 mentions) Bcl 2, by Santa Cruz Biotechnology (2 mentions) Abt 263, by Abbvie (2 mentions) Abt 737, by Abbvie (2 mentions) Cycloheximide (chx), by Merck Group (1 mentions) Doxycycline, by Merck Group (1 mentions) Gdc 0973, by Selleck Chemicals (1 mentions) Ci 1040, by Selleck Chemicals (1 mentions) S55746, by Selleck Chemicals (1 mentions) S63845, by Selleck Chemicals (1 mentions) Abt 737, by Selleck Chemicals (1 mentions) L glutamine, by Thermo Fisher Scientific (1 mentions) Epigallocatechin gallate (egcg), by Selleck Chemicals (1 mentions) Dimethyl α ketoglutarate, by Merck Group (1 mentions)

10 protocols using a 1210477

Isolation and Culture of Lymphoma Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Jeko‐1 cells were from DSMZ. Mino and JVM‐2 cells were from ATCC. CCMCL1 cells were obtained as described previously [32 (link)]. Lymphoma biopsies were obtained following protocols approved by the Institutional Review Board of the Cleveland Clinic. For patient samples of peripheral blood or bone marrow aspirates, mononuclear cells were isolated via Ficoll density gradient centrifugation, and PBMC or BMMC were used for further studies. For the preparation of cell suspension with lymphoma tissue specimen, briefly, razor blade was used to finely dice the tissue at first, followed by incubation with collagenase II and trypsin inhibitor. Cell suspension was then filtrated through 40 μM of cell strainer for further study. Immunoblotting antibodies are summarized in Table S1. Venetoclax [33 (link)], CDK9 inhibitors A‐1467729 and A‐1592668 [31 ], dinaciclib, and MCL‐1 inhibitor A‐1210477 [34 (link)] were obtained from AbbVie Inc. (North Chicago, IL). These inhibitors were dissolved in anhydrous DMSO at 10 mM and kept at −20°C for in vitro studies. Primary cells or cell lines were cultured in RPMI1640‐10% FBS medium with or without the indicated inhibitor(s) for 5 h before further experiment.

Zhao X., Bodo J., Chen R., Durkin L., Souers A.J., Phillips D.C, & Hsi E.D. (2020). Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma. EJHaem, 1(1), 161-169.

+ Open protocol

+ Expand

Combinatorial Drug Screening Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Venetoclax (VEN), A-1155463, and A-1210477 were provided by AbbVie. GDC-0973 (cobimetinib), CI1040, ABT-737, S63845, and S55746 were purchased from Selleckchem. Cycloheximide and doxycycline were purchased from Sigma-Aldrich.

Zhang Q., Riley-Gillis B., Han L., Jia Y., Lodi A., Zhang H., Ganesan S., Pan R., Konoplev S.N., Sweeney S.R., Ryan J.A., Jitkova Y., Dunner K J.r., Grosskurth S.E., Vijay P., Ghosh S., Lu C., Ma W., Kurtz S., Ruvolo V.R., Ma H., Weng C.C., Ramage C.L., Baran N., Shi C., Cai T., Davis R.E., Battula V.L., Mi Y., Wang J., DiNardo C.D., Andreeff M., Tyner J.W., Schimmer A., Letai A., Padua R.A., Bueso-Ramos C.E., Tiziani S., Leverson J., Popovic R, & Konopleva M. (2022). Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduction and Targeted Therapy, 7, 51.

+ Open protocol

+ Expand

Apoptosis pathway inhibitors protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

ABT-263, A-1331852 and A-1210477 were from AbbVie (North Chicago, IL, USA),
ABT-199, epigallocatechin gallate (EGCG), CB-839, simvastatin, rapamycin and
torin-1 from Selleck Chemicals (Houston, TX, USA),
gamma-L-glutamyl-p-nitroanilide (GPNA) from Insight
Biotechnology (Wembley, Middlesex, UK), azaserine from Cambridge Bioscience
(Cambridge, UK), aminooxyacetate (AOA), sodium palmitate, dimethyl
α-ketoglutarate, oxaloacetate and citrate from Sigma-Aldrich
(Gillingham, UK), L-glutamine from Life Technologies (Paisley, UK) and
GSK2194069, SB204990, atorvastatin, pitavastatin and bafilomycin A1 from Tocris
(Abingdon, UK). Antibodies against PARP, BCL-2, MCL-1, BAX, BAK and GAPDH were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA), caspase-3, caspase-9,
BCL-X_L, BCL-w, BIM, PUMA, BAD, IDH2, ACL, ACO2, ATG5 and ATG7
from Cell Signaling Technology (MA, USA), BID from Prof. J. Borst (The
Netherlands Cancer Institute, Amsterdam, the Netherlands), NOXA from Millipore
(Watford, UK) and SLC1A5, GLS, GFAT, GLUD1, IDH3, FASN and HMGR from Abcam
(Cambridge, UK).

Al-Zebeeby A., Vogler M., Milani M., Richards C., Alotibi A., Greaves G., Dyer M.J., Cohen G.M, & Varadarajan S. (2019). Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies. Haematologica, 104(5), 1016-1025.

+ Open protocol

+ Expand

Apoptosis Regulators Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

Imatinib, nilotinib and dasatinib were from Selleck Chemicals (Houston, TX, USA). ABT-737, ABT-199, A-1331852 and A-1210477 were kindly provided by AbbVie (North Chicago, IL, USA). Antibodies against BIM, PUMA, BMF, BIK, BAD, BCL-X_L and BCL-w were from Cell Signaling Technology (Danvers, MA, USA), GAPDH and MCL-1 from Santa Cruz Biotechnology (Santa Cruz, CA, USA), NOXA from Calbiochem (Darmstadt, Germany), BCL-2 from Dako (Ely, UK), BAX and BAK from Millipore (Watford, UK), HRK from Aviva Systems Biology (San Diego, CA, USA) and BID and BFL-1 were from Prof J Borst (The Netherlands Cancer Institute, Amsterdam, The Netherlands). All other reagents, unless mentioned otherwise, were from Sigma-Aldrich (St Louis, MO, USA).

Lucas C.M., Milani M., Butterworth M., Carmell N., Scott L.J., Clark R.E., Cohen G.M, & Varadarajan S. (2016). High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia. Leukemia, 30(6), 1273-1281.

+ Open protocol

+ Expand

Apoptosis-Inducing Protein Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols

ABT-199, A-1331852 and A-1210477 were kindly supplied by Abbvie Inc., (North Chicago, IL, USA). Peptides for BIM (MRPEIWIAQELRR IGDEFNA), BAD (LWAAQRYGRELR RMSDEFEGSFKGL), MS-1 (RPEIWMTQGLRRLGDEINAYYAR), HRK (WSSAAQLTAARLKALGDELHQ) and PUMA-2A (EQWAREIGAQARRMAADLNA) were from New England Peptide (Gardner, MA, USA) or GenScript (Piscataway, NJ, USA). Other reagents were from Sigma-Aldrich Co. (St. Louis, MO, USA).

Butterworth M., Pettitt A., Varadarajan S, & Cohen G.M. (2016). BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells. British Journal of Cancer, 114(6), 638-641.

+ Open protocol

+ Expand

Cytotoxicity evaluation of anti-apoptotic inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fetal bovine serum, RPMI 1640 medium, insulin, p-Nitrophenyl Phosphate Substrate (pNPP), Thiazolyl Blue Tetrazolium Bromide (MTT), dimethyl sulfoxide (DMSO), Hoechst 33588, and propidium iodide (PI) came from Sigma-Aldrich (Dublin, Ireland). DMEM medium was purchased from Lonza (Analab Ltd, Lisburn, United Kindom) and DMEM/F12 from Gibco (Biosciences, Dún Laoghaire, Ireland). ABT199 was purchased from Active Biochem (Maplewood, NJ, USA), WEHI-539 from ChemScene (South Brunswick, NJ, USA) and A-1210477 was obtained from AbbVie (North Chicago, IL, USA). Cisplatin and paclitaxel were purchased from Selleckchem (Stratech Scientific Ltd, Newmarket, United Kindom).

Lucantoni F., Lindner A.U., O’Donovan N., Düssmann H, & Prehn J.H. (2018). Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells. Cell Death & Disease, 9(2), 42.

+ Open protocol

+ Expand

In Vitro Evaluation of Anti-Leukemic Compounds

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mouse p185⁺Arf^−/− B-ALL were grown in RPMI (Life Technologies, CA) with 10% fetal bovine serum, 55 μM 2-mercaptoethanol, 2 mM glutamine, penicillin, and streptomycin. Navitoclax (ABT-263), venetoclax (ABT-199), A-1155463, and A-1210477 were kindly provided by AbbVie, IL. EU-5346 (also known as Compound #9) was provided by Eutropic Pharmaceutical, MA [30 (link)]. UM-36 was kindly provided by Dr. Nikolovska-Coleska [28 (link), 29 (link)]. All compounds were solubilized in DMSO and added at indicated concentrations for cell culture assays.

Koss B., Ryan J., Budhraja A., Szarama K., Yang X., Bathina M., Cardone M.H., Nikolovska-Coleska Z., Letai A, & Opferman J.T. (2016). Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines. Oncotarget, 7(10), 11500-11511.

+ Open protocol

+ Expand

Probing Apoptosis Regulators in Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

A-1331852 and A-1210477 from AbbVie Inc. (North Chicago, IL, USA), S63845 from ActiveBiochem (New Jersey, USA), and ABT-199 and Z-VAD.FMK from Selleck Chemicals Co. (Houston, TX, USA) were used. Antibodies against BCL-X_L, BIM and BAD from Cell Signalling Technology (MA, USA), NOXA from Millipore (Watford, UK), BID and tubulin from Abcam (Cambridge, UK), MCL-1, BCL-2 and PUMA from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and BAX and cytochrome c (BD BioSciences, California) were used for immunoblotting. Antibodies used for immunoprecipitation were MCL-1 (Y-37) and BCL-X_L from Abcam, BCL-2 from BD Biosciences and BAX (NT) from Merck-Millipore (Burlington, MA, USA). siRNAs specific to BCL-X_L (SI03025141), MCL-1 (SI02781205) and a non-targeting control (1027310) from Qiagen (Cambridge, UK) were incubated with Interferin siRNA transfection reagent (Polyplus transfection Inc., NY, USA) and added to cells at a concentration of 10 nM for 72 h.

Greaves G., Milani M., Butterworth M., Carter R.J., Byrne D.P., Eyers P.A., Luo X., Cohen G.M, & Varadarajan S. (2018). BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL. Cell Death and Differentiation, 26(6), 1037-1047.

+ Open protocol

+ Expand

Anticancer Compounds from Diverse Sources

Cited 5 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

ABT-737, ABT-263, ABT-199, A-1331852 and A-1210477 were kindly provided by AbbVie Inc. (North Chicago, IL, USA). Compounds 10, 20, 21, 22, 36, 37 and 41 were provided by Dr. Z Nikolovska-Coleska (University of Michigan, Ann Arbor, MI, USA).^{8 (link)} Compound 9 was custom-synthesised and purchased from Molport (Riga, Latvia).^{6 (link)} MIM-1 and the stapled peptides against MCL-1 and NOXA were kindly provided by Dr. L Walensky (Dana-Farber Cancer Institute, Boston, MA, USA).^{7 (link), 16 (link)} Maritoclax was provided by Professor H-G Wang (Pennsylvania State University College of Medicine, Hershey, PA, USA).^{10 (link)} Apogossypol, Sabutoclax and BI112D1 were provided by Professor M. Pellecchia (Sanford-Burnham Institute, La Jolla, CA, USA).^{11 (link), 12 (link)} Gossypol, Obatoclax and TW-37 were obtained from Selleck Chemicals Co. (Houston, TX, USA).

Milani M., Byrne D.P., Greaves G., Butterworth M., Cohen G.M., Eyers P.A, & Varadarajan S. (2017). DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis. Cell Death & Disease, 8(1), e2552-.

+ Open protocol

+ Expand

Targeted Combination Therapy Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Venetoclax and A-1210477 were provided by AbbVie (North Chicago, IL). GDC-0980, taselisib, and GDC-0491 were obtained from Genentech (South San Francisco CA).

Rahmani M., Nkwocha J., Hawkins E., Pei X., Parker R.E., Kmieciak M., Leverson J.D., Sampath D., Ferreira-Gonzalez A, & Grant S. (2018). Co-targeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells. Cancer research, 78(11), 3075-3086.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!